Early diagnostics and therapeutics for Alzheimer’s disease – how early can we get there?

References

• Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat. Rep.53(15), 1–48 (2005).
   Google Scholar
• Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. Science235, 1641–1644 (1987).
   PubMed Web of Science ®Google Scholar
• Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurologisches Centralblatt23, 1129–1136 (1906).
   Google Scholar
• Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down’s syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis.3(1), 16–32 (1996).
   PubMed Web of Science ®Google Scholar
• Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu. Rev. Neurosci.24, 1121–1159 (2001).
   PubMed Web of Science ®Google Scholar
• Morishima-Kawashima M, Hara Y. Alzheimer’s disease: β-amyloid protein and tau. J. Neurosci. Res.70(3), 392–401 (2002).
   PubMed Web of Science ®Google Scholar
• Kowalska A. Genetic basis of neurodegeneration in familial Alzheimer’s disease. Pol. J. Pharmacol.56(2), 171–178 (2004).
   PubMedGoogle Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science256(5054), 184–185 (1992).
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science297(5580), 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• Klein WL, Stine WB Jr, Teplow DB. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiol. Aging25(5), 569–580 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans.30(4), 552–557 (2002).
   PubMed Web of Science ®Google Scholar
• Knopman DS, DeKosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56(9), 1143–1153 (2001).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Alzheimer’s disease. N. Engl. J. Med.351(1), 56–67 (2004).
   PubMed Web of Science ®Google Scholar
• Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer’s disease. Nat. Med.10(Suppl.), S34–S41 (2004).
   PubMed Web of Science ®Google Scholar
• Kawas CH, Corrada MM, Brookmeyer R et al. Visual memory predicts Alzheimer’s disease more than a decade before diagnosis. Neurology60(7), 1089–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol.58(9), 1395–1402 (2001).
   PubMed Web of Science ®Google Scholar
• Feldman HH, Jacova C. Mild cognitive impairment. Am. J. Geriatr. Psychiatry13(8), 645–655 (2005).
   PubMedGoogle Scholar
• Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl Acad. Sci. USA100(1), 330–335 (2003).
   PubMed Web of Science ®Google Scholar
• Riek R, Guntert P, Döbeli H, Wipf B, Wüthrich K. NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, Aβ(1–40)ox and Aβ(1–42)ox. Eur. J. Biochem.268(22), 5930–5936 (2001).
   PubMedGoogle Scholar
• Hou L, Shao H, Zhang Y et al. Solution NMR studies of the Aβ(1–40) and Aβ(1–42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J. Am. Chem. Soc.126(7), 1992–2005 (2004).
   PubMed Web of Science ®Google Scholar
• Lazo ND, Grant MA, Condron MM, Rigby AC, Teplow DB. On the nucleation of amyloid β–protein monomer folding. Protein Sci.14, 1581–1596 (2005).
   PubMed Web of Science ®Google Scholar
• Sun XD, Mo ZL, Taylor BM, Epps DE. A slowly formed transient conformer of Aβ(1–40) is toxic to inward channels of dissociated hippocampal and cortical neurons of rats. Neurobiol. Dis.14(3), 567–578 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature416(6880), 535–539 (2002).
   PubMed Web of Science ®Google Scholar
• Bitan G, Lomakin A, Teplow DB. Amyloid β-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem.276(37), 35176–35184 (2001).
   PubMed Web of Science ®Google Scholar
• Lambert MP, Barlow AK, Chromy BA et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA95(11), 6448–6453 (1998).
   PubMed Web of Science ®Google Scholar
• Gong Y, Chang L, Viola KL et al. Alzheimer’s disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA100(18), 10417–10422 (2003).
   PubMed Web of Science ®Google Scholar
• Barghorn S, Nimmrich V, Striebinger A et al. Globular amyloid β-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J. Neurochem.95(3), 834–847 (2005).
   PubMed Web of Science ®Google Scholar
• Lazo ND, Maji SK, Fradinger EA, Bitan G, Teplow DB. The amyloid β-protein. In: Amyloid Proteins - The β-Sheet Conformation and Disease. Sipe, JD (Ed.). Wiley-VCH, Weinheim, Germany, 385–448 (2005).
   Google Scholar
• Walsh DM, Hartley DM, Kusumoto Y et al. Amyloid β-protein fibrillogenesis – structure and biological activity of protofibrillar intermediates. J. Biol. Chem.274(36), 25945–25952 (1999).
   PubMed Web of Science ®Google Scholar
• Serpell LC. Alzheimer’s amyloid fibrils: structure and assembly. Biochim. Biophys. Acta1502(1), 16–30 (2000).
   PubMed Web of Science ®Google Scholar
• Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer’s β-amyloid fibrils. Science307(5707), 262–265 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson M, Bocharova OV, Makarava N, Breydo L, Salnikov VV, Baskakov IV. Polymorphism and ultrastructural organization of prion protein amyloid fibrils: an insight from high resolution atomic force microscopy. J. Mol. Biol.358(2), 580–596 (2006).
   PubMed Web of Science ®Google Scholar
• Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ42 fibrils. Science293(5534), 1491–1495 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis J, Dickson DW, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science293(5534), 1487–1491 (2001).
   PubMed Web of Science ®Google Scholar
• Oddo S, Caccamo A, Tran L et al. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J. Biol. Chem.281(3), 1599–1604 (2006).
   PubMed Web of Science ®Google Scholar
• Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer’s disease. Neurosci. Res.54(3), 197–201 (2006).
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging22(6), 799–809 (2001).
   PubMed Web of Science ®Google Scholar
• Tuppo EE, Forman LJ. Free radical oxidative damage and Alzheimer’s disease. J. Am. Osteopath. Assoc.101(Suppl. 12 Pt 1), S11–S15 (2001).
   PubMedGoogle Scholar
• Takuma K, Yan SS, Stern DM, Yamada K. Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer’s disease. J. Pharmacol. Sci.97(3), 312–316 (2005).
   PubMed Web of Science ®Google Scholar
• Barger SW. An unconventional hypothesis of oxidation in alzheimer’s disease: intersections with excitotoxicity. Front. Biosci.9, 3286–3295 (2004).
   PubMed Web of Science ®Google Scholar
• Glabe CC. Amyloid accumulation and pathogensis of Alzheimer’s disease: significance of monomeric, oligomeric and fibrillar Aβ. Subcell. Biochem.38, 167–177 (2005).
   PubMedGoogle Scholar
• Perry G, Nunomura A, Hirai K et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer’s and other neurodegenerative diseases? Free Radic. Biol. Med.33(11), 1475–1479 (2002).
   PubMed Web of Science ®Google Scholar
• Kayed R, Head E, Thompson JL et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science300(5618), 486–489 (2003).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev.81(2), 741–766 (2001).
   PubMed Web of Science ®Google Scholar
• Ye CP, Selkoe DJ, Hartley DM. Protofibrils of amyloid β-protein inhibit specific K+ currents in neocortical cultures. Neurobiol. Dis.13(3), 177–190 (2003).
   PubMed Web of Science ®Google Scholar
• Ye C, Walsh DM, Selkoe DJ, Hartley DM. Amyloid β-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci. Lett.366(3), 320–325 (2004).
   PubMed Web of Science ®Google Scholar
• Nilsberth C, Westlind-Danielsson A, Eckman CB et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Aβ protofibril formation. Nat. Neurosci.4(9), 887–893 (2001).
   PubMed Web of Science ®Google Scholar
• Haass C, Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat. Neurosci.4(9), 859–860 (2001).
   PubMed Web of Science ®Google Scholar
• Rowan MJ, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer’s disease. Philos. Trans. R. Soc. Lond. Ser. B-Biol. Sci.358(1432), 821–828 (2003).
   PubMed Web of Science ®Google Scholar
• Morgan D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem. Res.28(7), 1029–1034 (2003).
   PubMed Web of Science ®Google Scholar
• Hsia AY, Masliah E, McConlogue L et al. Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc. Natl Acad. Sci. USA96(6), 3228–3233 (1999).
   PubMed Web of Science ®Google Scholar
• Mucke L, Masliah E, Yu GQ et al. High-level neuronal expression of Aβ(1–42) in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci.20(11), 4050–4058 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobsen JS, Wu C-C, Redwine JM et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA103(13), 5161–5166 (2006).
   PubMed Web of Science ®Google Scholar
• Lesné S, Koh MT, Kotilinek L et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature440(7082), 352–357 (2006).
   PubMed Web of Science ®Google Scholar
• Wang HY, Lee DHS, D’Andrea MR, Peterson PA, Shank RP, Reitz AB. β-amyloid(1–42) binds to α7 nicotinic acetylcholine receptor with high affinity – implications for Alzheimer’s disease pathology. J. Biol. Chem.275(8), 5626–5632 (2000).
   PubMed Web of Science ®Google Scholar
• Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci.26, 267–298 (2003).
   PubMed Web of Science ®Google Scholar
• Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC. The channel hypothesis of Alzheimer’s disease: current status. Peptides23(7), 1311–1315 (2002).
   PubMed Web of Science ®Google Scholar
• Kayed R, Sokolov Y, Edmonds B et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem.279(45), 46363–46366 (2004).
   PubMed Web of Science ®Google Scholar
• Crowther DC, Kinghorn KJ, Miranda E et al. Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer’s disease. Neuroscience132(1), 123–135 (2005).
   PubMed Web of Science ®Google Scholar
• Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann. Neurol.45(3), 358–368 (1999).
   PubMed Web of Science ®Google Scholar
• Duyckaerts C, Dickson DW. Neuropathology of Alzheimer’s disease. In: Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Dickson DW (Ed.). ISN Neuropath Press, Basel, Switzerland, 47–65 (2003).
   Google Scholar
• Mesulam MM. Aging, Alzheimer’s disease and dementia. In: Principles of Behavioral and Cognitive Neurology. Mesulam MM (Ed.). Oxford University Press, Oxford, UK, 439–510 (2000).
   Google Scholar
• Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology64(5), 834–841 (2005).
   PubMed Web of Science ®Google Scholar
• Jicha GA, Parisi JE, Dickson DW et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol.63(5), 674–681 (2006).
   PubMed Web of Science ®Google Scholar
• Knopman DS, Parisi JE, Salviati A et al. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol.62(11), 1087–1095 (2003).
   PubMed Web of Science ®Google Scholar
• Arendt T. Neurodegeneration and plasticity. Int. J. Dev. Neurosci.22(7), 507–514 (2004).
   PubMed Web of Science ®Google Scholar
• Giannakopoulos P, Hof PR, Bouras C. Selective vulnerability of neocortical association areas in Alzheimer’s disease. Microsc. Res. Tech.43(1), 16–23 (1998).
   PubMed Web of Science ®Google Scholar
• Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease. Neurobiol. Aging25(1), 5–18 (2004).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol. Aging25(1), 19–23 (2004).
   PubMed Web of Science ®Google Scholar
• Larrieu S, Letenneur L, Orgogozo JM et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology59(10), 1594–1599 (2002).
   PubMed Web of Science ®Google Scholar
• Tervo S, Kivipelto M, Hanninen T et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement. Geriatr. Cogn.17(3), 196–203 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Doody R, Kurz A et al. Current concepts in mild cognitive impairment. Arch. Neurol.58(12), 1985–1992 (2001).
   PubMed Web of Science ®Google Scholar
• Petersen RC. Aging, mild cognitive impairment, and Alzheimer’s disease. Neurol. Clin.18(4), 789–806 (2000).
   PubMed Web of Science ®Google Scholar
• Pasquier F. Early diagnosis of dementia: neuropsychology. J. Neurol.246(1), 6–15 (1999).
   PubMedGoogle Scholar
• Cummings JL. Alzheimer’s disease. In: The Neuropsychiatry of Alzheimer’s Disease and Related Dementias. Cummings JL (Ed.). Martin Dunitz Ltd, London, UK, 57–116 (2003).
   Google Scholar
• Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc.53(4), 695–699 (2005).
   PubMed Web of Science ®Google Scholar
• Kalbe E, Kessler J, Calabrese P et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int. J. Geriatr. Psychiatry19(2), 136–143 (2004).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Petersen RC, Xu Y et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology55(4), 484–489 (2000).
   PubMed Web of Science ®Google Scholar
• Du AT, Schuff N, Chao LL et al. White matter lesions are associated with cortical atrophy more than entorhinal and hippocampal atrophy. Neurobiol. Aging26(4), 553–559 (2005).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Shiung MM, Gunter JL et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology62(4), 591–600 (2004).
   PubMed Web of Science ®Google Scholar
• Apostolova LG, Dutton RA, Dinov ID et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch. Neurol. (63), 693–699 (2006).
   PubMedGoogle Scholar
• Thompson PM, Hayashi KM, De Zubicaray GI et al. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage22(4), 1754–1766 (2004).
   PubMed Web of Science ®Google Scholar
• Apostolova LG, Dinov ID, Dutton RA et al. 3D comparison of hippocampal atrophy in mild cognitive impairment and Alzheimer’s disease. Neurology665(Suppl. 2 5), A60 (2006).
   Google Scholar
• Du AT, Schuff N, Kramer JH et al. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology62(3), 422–427 (2004).
   PubMed Web of Science ®Google Scholar
• deToledo-Morrell L, Stoub TR, Bulgakova M et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol. Aging25(9), 1197–1203 (2004).
   PubMed Web of Science ®Google Scholar
• Karas GB, Scheltens P, Rombouts SA et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer’s disease. Neuroimage23(2), 708–716 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson PM, Hayashi KM, de Zubicaray G et al. Dynamics of gray matter loss in Alzheimer’s disease. J. Neurosci.23(3), 994–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Apostolova LG, Steiner CA, Akopyan GG, Toga AW, Cummings JL, Thompson PM. Gray matter atrophy in mild cognitive impairment and mild Alzheimer’s disease. Neurology66(5), Suppl. 2(5) (2006).
   Google Scholar
• Kantarci K, Reynolds G, Petersen RC et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am. J. Neuroradiol.24(5), 843–849 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarci K, Petersen RC, Boeve BF et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology64(5), 902–904 (2005).
   PubMed Web of Science ®Google Scholar
• Rombouts SA, Barkhof F, Veltman DJ et al. Functional MR imaging in Alzheimer’s disease during memory encoding. AJNR Am. J. Neuroradiol.21(10), 1869–1875 (2000).
   PubMed Web of Science ®Google Scholar
• Sperling RA, Bates JF, Chua EF et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry74(1), 44–50 (2003).
   PubMed Web of Science ®Google Scholar
• Dickerson BC, Salat DH, Bates JF et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol.56(1), 27–35 (2004).
   PubMed Web of Science ®Google Scholar
• Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging32(4), 486–510 (2005).
   PubMed Web of Science ®Google Scholar
• Silverman DH, Truong CT, Kim SK et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol. Genet. Metab.80(3), 350–355 (2003).
   PubMed Web of Science ®Google Scholar
• Nordberg A. PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol.3(9), 519–527 (2004).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer’s disease. Clin. Neurol. Neurosurg.107(3), 165–173 (2005).
   PubMed Web of Science ®Google Scholar
• Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology60(4), 652–656 (2003).
   PubMed Web of Science ®Google Scholar
• Blennow K. CSF biomarkers for mild cognitive impairment. J. Intern. Med.256(3), 224–234 (2004).
   PubMed Web of Science ®Google Scholar
• Hampel H, Teipel SJ, Fuchsberger T et al. Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol. Psychiatry9(7), 705–710 (2004).
   PubMed Web of Science ®Google Scholar
• Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx1(2), 226–234 (2004).
   PubMedGoogle Scholar
• Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer’s patients by fluorescence correlation spectroscopy. Nat. Med.4(7), 832–834 (1998).
   PubMed Web of Science ®Google Scholar
• Georganopoulou DG, Chang L, Nam JM et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc. Natl Acad. Sci. USA102(7), 2273–2276 (2005).
   PubMed Web of Science ®Google Scholar
• Kamali-Moghaddam M, Englund H, Schallmeiner E et al. Proximity ligation-based detection of biomarkers of protein folding disorders. Cambridge Healthtech Institute’s 10th Annual Transmissible Spongiform Encepalopathies Meeting, Baltimore, MD, USA (2006).
   Google Scholar
• Fradinger EA, Bitan G. En route to early diagnosis of Alzheimer’s disease – are we there yet? Trends Biotechnol.23(11), 531–533 (2005).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J. Neurol. Neurosurg. Psychiatry77(4), 429–438 (2006).
   PubMed Web of Science ®Google Scholar
• Vassar R. BACE1: the β-secretase enzyme in Alzheimer’s disease. J. Mol. Neurosci.23(1–2), 105–114 (2004).
   PubMed Web of Science ®Google Scholar
• Hook V, Toneff T, Bogyo M et al. Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer’s disease. Biol. Chem.386(9), 931–940 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt B, Baumann S, Braun HA, Larbig G. Inhibitors and modulators of β- and γ-secretase. Curr. Top. Med. Chem.6(4), 377–392 (2006).
   PubMed Web of Science ®Google Scholar
• Citron M. β-secretase inhibition for the treatment of Alzheimer’s disease – promise and challenge. Trends Pharmacol. Sci.25(2), 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Chen F, Hasegawa H, Schmitt-Ulms G et al. TMP21 is a presenilin complex component that modulates γ-secretase but not ε-secretase activity. Nature440(7088), 1208–1212 (2006).
   PubMed Web of Science ®Google Scholar
• Churcher I, Beher D. γ-secretase as a therapeutic target for the treatment of Alzheimer’s disease. Curr. Pharm. Des.11(26), 3363–3382 (2005).
   PubMed Web of Science ®Google Scholar
• Spires TL, Hyman BT. Transgenic models of Alzheimer’s disease: learning from animals. NeuroRx2(3), 423–437 (2005).
   PubMedGoogle Scholar
• Tomita T, Iwatsubo T. γ-secretase as a therapeutic target for treatment of Alzheimer’s disease. Curr. Pharm. Des.12(6), 661–670 (2006).
   PubMed Web of Science ®Google Scholar
• Espeseth AS, Xu M, Huang Q et al. Compounds that bind APP and inhibit Aβ processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J. Biol. Chem.280(18), 17792–17797 (2005).
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Black S, Haworth J et al. A placebo-controlled, double-blind trial of the selective Aβ-42 lowering agent, flurizan (MPC-7869, (R)-flurbiprofen) in patients with mild to moderate Alzheimer’s disease. Alzheimer’s Association International Conference on Prevention of Dementia, Washington, DC, USA (2005).
   Google Scholar
• Caccamo A, Oddo S, Billings LM et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron49(5), 671–682 (2006).
   PubMed Web of Science ®Google Scholar
• Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA94(8), 4109–4112 (1997).
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400(6740), 173–177 (1999).
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med.9(4), 448–452 (2003).
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64(9), 1553–1562 (2005).
   PubMed Web of Science ®Google Scholar
• Cribbs DH, Ghochikyan A, Vasilevko V et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. Int. Immunol.15(4), 505–514 (2003).
   PubMed Web of Science ®Google Scholar
• Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-β immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res.9(1), 77–84 (2006).
   PubMed Web of Science ®Google Scholar
• Ghochikyan A, Mkrtichyan M, Petrushina I et al. Prototype Alzheimer’s disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch. Vaccine24(13), 2275–2282 (2006).
   PubMed Web of Science ®Google Scholar
• Morelli L, Bulloj A, Leal MC, Castano EM. Amyloid β degradation: a challenging task for brain peptidases. Subcell. Biochem.38, 129–145 (2005).
   PubMedGoogle Scholar
• Iwata N, Higuchi M, Saido TC. Metabolism of amyloid-β peptide and Alzheimer’s disease. Pharmacol. Ther.108(2), 129–148 (2005).
   PubMed Web of Science ®Google Scholar
• Soto C, Estrada L. Amyloid inhibitors and β-sheet breakers. Subcell. Biochem.38, 351–364 (2005).
   PubMedGoogle Scholar
• Lowe TL, Strzelec A, Kiessling LL, Murphy RM. Structure–function relationships for inhibitors of β-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry40(26), 7882–7889 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Sciarretta KL, Meredith SC. Inhibition of β-amyloid(40) fibrillogenesis and disassembly of β-amyloid(40) fibrils by short β-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry40(28), 8237–8245 (2001).
   PubMed Web of Science ®Google Scholar
• Mason JM, Kokkoni N, Stott K, Doig AJ. Design strategies for anti-amyloid agents. Curr. Opin. Struct. Biol.13(4), 526–532 (2003).
   PubMed Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem.280(7), 5892–5901 (2005).
   PubMed Web of Science ®Google Scholar
• De Felice FG, Vieira MN, Saraiva LM et al. Targeting the neurotoxic species in Alzheimer’s disease: inhibitors of Aβ oligomerization. FASEB J.18(12), 1366–1372 (2004).
   PubMed Web of Science ®Google Scholar
• Wang Z, Chang L, Klein WL, Thatcher GR, Venton DL. Per-6-substituted-per-6-deoxy β-cyclodextrins inhibit the formation of β-amyloid peptide derived soluble oligomers. J. Med. Chem.47(13), 3329–3333 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Townsend M, Podlisny MB et al. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J. Neurosci.25(10), 2455–2462 (2005).
   PubMed Web of Science ®Google Scholar
• McLaurin J, Kierstead ME, Brown ME et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med.12(7), 801–808 (2006).
   PubMed Web of Science ®Google Scholar
• Atwood CS, Moir RD, Huang X et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem.273(21), 12817–12826 (1998).
   PubMed Web of Science ®Google Scholar
• Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-β in Alzheimer’s disease. Int. J. Exp. Pathol.86(3), 147–159 (2005).
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Bush AI, Mackinnon A et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol.60(12), 1685–1691 (2003).
   PubMed Web of Science ®Google Scholar
• Takeda M, Tanaka T, Cacabelos R. In: Molecular Neurobiology of Alzheimer Disease and Related Disorders. Takeda M, Tanaka T, Cacabelos R (Eds). Karger AG, Basel, Switzerland, X–XII (2004).
   Google Scholar